gsk

Jemperli (dostarlimab) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer

GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II and III ...
gsk

GSK showcases pipeline momentum across lung, gynaecological and gastrointestinal cancers at ESMO 2026

AZUR-1 data to show clinically meaningful sustained complete responses with Jemperli (dostarlimab) in MSI-H/dMMR locally advanced rectal cancer GSK plc (LSE/NYSE: GSK) will present more than 20 ...
gsk

ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with ...

CROWN is the first large, phase IIIb international trial to evaluate the investigational use of long-acting Cabenuva versus daily oral therapy in people with a history of antiretroviral treatment and ...